Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. by Tentori, Lucio et al.
HAL Id: pasteur-01164062
https://hal-riip.archives-ouvertes.fr/pasteur-01164062
Submitted on 16 Jun 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Pharmacological inhibition of poly(ADP-ribose)
polymerase-1 modulates resistance of human
glioblastoma stem cells to temozolomide.
Lucio Tentori, Lucia Ricci-Vitiani, Alessia Muzi, Fabio Ciccarone, Federica
Pelacchi, Roberta Calabrese, Daniele Runci, Roberto Pallini, Paola Caiafa,
Grazia Graziani
To cite this version:
Lucio Tentori, Lucia Ricci-Vitiani, Alessia Muzi, Fabio Ciccarone, Federica Pelacchi, et al.. Pharmaco-
logical inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem
cells to temozolomide.. BMC Cancer, BioMed Central, 2014, 14, pp.151. ￿10.1007/s00280-013-2175-0￿.
￿pasteur-01164062￿
Tentori et al. BMC Cancer 2014, 14:151
http://www.biomedcentral.com/1471-2407/14/151RESEARCH ARTICLE Open AccessPharmacological inhibition of poly(ADP-ribose)
polymerase-1 modulates resistance of human
glioblastoma stem cells to temozolomide
Lucio Tentori1*†, Lucia Ricci-Vitiani2†, Alessia Muzi1, Fabio Ciccarone3,5, Federica Pelacchi2, Roberta Calabrese3,5,
Daniele Runci2, Roberto Pallini4, Paola Caiafa3,5 and Grazia Graziani1*Abstract
Background: Chemoresistance of glioblastoma multiforme (GBM) has been attributed to the presence within
the tumor of cancer stem cells (GSCs). The standard therapy for GBM consists of surgery followed by
radiotherapy and the chemotherapeutic agent temozolomide (TMZ). However, TMZ efficacy is limited by
O6-methylguanine-DNA-methyltransferase (MGMT) and Mismatch Repair (MMR) functions. Strategies to
counteract TMZ resistance include its combination with poly(ADP-ribose) polymerase inhibitors (PARPi), which
hamper the repair of N-methylpurines. PARPi are also investigated as monotherapy for tumors with deficiency of
homologous recombination (HR). We have investigated whether PARPi may restore GSC sensitivity to TMZ or
may be effective as monotherapy.
Methods: Ten human GSC lines were assayed for MMR proteins, MGMT and PARP-1 expression/activity, MGMT
promoter methylation and sensitivity to TMZ or PARPi, alone and in combination. Since PTEN defects are
frequently detected in GBM and may cause HR dysfunction, PTEN expression was also analyzed. The statistical
analysis of the differences in drug sensitivity among the cell lines was performed using the ANOVA and
Bonferroni’s post-test or the non-parametric Kruskal-Wallis analysis and Dunn’s post-test for multiple comparisons.
Synergism between TMZ and PARPi was analyzed by the median-effect method of Chou and Talalay. Correlation
analyses were done using the Spearman’s rank test.
Results: All GSCs were MMR-proficient and resistance to TMZ was mainly associated with high MGMT activity or low
proliferation rate. MGMT promoter hypermethylation of GSCs correlated both with low MGMT activity/expression
(Spearman’s test, P = 0.004 and P = 0.01) and with longer overall survival of GBM patients (P = 0.02). Sensitivity of
each GSC line to PARPi as single agent did not correlate with PARP-1 or PTEN expression. Notably, PARPi and
TMZ combination exerted synergistic antitumor effects in eight out of ten GSC lines and the TMZ dose reduction
achieved significantly correlated with the sensitivity of each cell line to PARPi as single agent (P = 0.01).
Conclusions: The combination of TMZ with PARPi may represent a valuable strategy to reverse GSC
chemoresistance.
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Glioblastoma multiforme (GBM) is the most common
and aggressive malignant primary brain tumor in adults.
Prognosis remains very poor because neoplastic cells in-
vade the brain parenchyma and are naturally resistant to
most cytotoxic drugs and radiotherapy [1]. Due to the in-
filtrative nature of GBM, neurosurgical intervention is not
curative. Presently, the current standard of care for pa-
tients with newly diagnosed GBM is surgical resection
followed by fractionated external beam radiotherapy and
systemic temozolomide (TMZ), a methylating agent that
crosses the blood–brain barrier [2,3]. However, this treat-
ment modality is not curative and the vast majority of pa-
tients experience recurrent disease. Currently, there is no
standard treatment for patients with recurrent/resistant
GBM, whose median overall survival is only 7 months.
The efficacy of TMZ is limited by the functional status
of DNA damage repair systems such as the O6-methylgua-
nine-DNA-methyltransferase (MGMT), the Mismatch Re-
pair complex (MMR) and the Base Excision Repair system
(BER) [4-6]. In cells with low MGMT levels, unrepaired
O6-methylguanine mispairs with cytosine or thymine and
the resulting mismatches are recognized by the MMR [4].
However, since MMR removes only the base opposite to
O6-methylguanine, the methylated base persists and mis-
pairs again with thymine. This cycle is repeated with each
round of DNA replication, eventually resulting in DNA
breaks and cell death. Thus, tumor sensitivity to TMZ re-
quires both low MGMT levels and a functional MMR.
About half of GBMs show MGMT promoter hypermethy-
lation with low levels of MGMT expression; in these cases
MGMT promoter hypermethylation is associated with
prolonged survival of patients treated with TMZ [7]. Def-
icit in MMR function results in tolerance to TMZ, regard-
less of MGMT activity levels, and reduced expression of
MMR proteins has been frequently reported in human
GBMs including those that recur after TMZ [8]. However,
TMZ-resistant GBM cells have been described that are
MGMT-deficient and MMR-proficient, suggesting that
the mechanisms of TMZ resistance are more complex [9].
Among the experimental protocols aimed at increasing
TMZ efficacy, an innovative one is based on the association
of TMZ with inhibitors of poly(ADP-ribose) polymerase-1
(PARP-1), an enzyme that regulates different cellular pro-
cesses including DNA repair [5]. Most of the PARP inhibi-
tors (PARPi) in clinical development bind to the catalytic
domain of the enzyme and prevent the synthesis of ADP-
ribose polymers from NAD+ substrate. In preclinical stud-
ies, PARPi have been shown to enhance TMZ antitumor
activity against GBM human xenografts [10-13] and PARPi
are under clinical evaluation in combination with TMZ for
the treatment of recurrent or refractory GBM (www.clini-
caltrials.gov). The mechanism underlying the synergy be-
tween PARPi and TMZ relies on the inhibition of therepair of N-methylpurines (i.e., N7-methylguanine and N3-
methyladenine) generated by the methylating agent. In fact,
these damaged bases normally do no contribute to TMZ
cytotoxicity being promptly repaired by the BER system, in
which PARP-1 plays a key role. Thus, the enhancing effect
exerted by PARPi on temozolomide antitumor activity de-
rives from an increased DNA damage that eventually re-
sults in apoptosis and/or growth arrest [5,12].
In addition, PARPi are currently investigated as mono-
therapy in Breast Cancer gene (BRCA) mutated and hom-
ologous recombination (HR) defective tumors, according
to a synthetic lethality model. PARP-1 is required for the
repair of single strand breaks (SSB); thus, cells with inhib-
ited PARP activity may acquire more unrepaired SSB that,
when encounter DNA replication forks, result in fork col-
lapse and DNA double strand breaks (DSB) formation. In
normal cells with a functional HR the DSB are repaired,
whereas in tumor cells with defective HR the DSB persist
and cause cell death [14,15]. Besides mutations or lack of
expression of BRCA molecules, deficiency of several other
proteins involved in the HR pathway may sensitize cancer
cells to PARPi. One example is represented by phosphat-
ase and tensin homolog (PTEN) that is frequently mu-
tated/deleted in GBM [16] and that, among its functions,
also regulates transcription of RAD51, an important HR
component [17].
Recently, a subset of tumor cells has been identified in
GBM that shows stem cell-like features and that is be-
lieved to be responsible for tumor initiation and recur-
rence [18,19]. These cells are generally referred to as GBM
stem cells (GSCs). We first demonstrated that GSCs are
highly resistant to conventional chemotherapy due to their
enhanced DNA repair pathways and drug efflux mecha-
nisms [20]. Therefore, GSCs represent a unique model to
investigate whether PARPi may restore sensitivity to TMZ
or may be effective as monotherapy in PTEN-deficient
GBM. In the present study, we demonstrate that PARP-1
can be efficiently targeted in cancer stem cells in order to
increase GBM sensitivity to TMZ and that the potentiating
effect induced by PARPi directly correlated with the sensi-
tivity of each cell line to the PARPi used as monotherapy.
Methods
Cell cultures
GSCs were isolated from surgical samples of adult patients
who had undergone craniotomy at the Institute of Neuro-
surgery, “Università Cattolica del Sacro Cuore”, School of
Medicine, Rome, Italy. Before surgery all patients provided
written informed consent according to the Declaration of
Helsinki and the research proposal was approved by the
Ethical Committee of the “Università Cattolica del Sacro
Cuore” (Rome, Italy). The diagnosis of GBM was established
on histological examination according to the WHO classifi-
cation of tumors of the nervous system. Tumor samples
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suspension was cultured in a serum-free medium supple-
mented with 20 ng/ml EGF and 10 ng/ml FGF-2. Gener-
ation of GSCs was defined by the following criteria: in vitro
formation of primary neurospheres expressing stem cell
markers such as CD133, SOX2, Musashi-1 and nestin, cap-
acity of self-renew, ability to co-express astrocytic as well as
neuronal phenotypic markers after serum-induced differen-
tiation in vitro [20,21]. For immunofluorescence analysis
cells were fixed with 4% paraformaldehyde and stained
with antibodies directed against SOX2 (goat poly-
clonal; R&D Systems; 1:200) or Musashi-1 (MAB 2628;
R&D Systems; 1:200) or nestin (rabbit polyclonal; Sigma
N5413; 1:200). As secondary antibodies, goat anti-rabbit
fluorescein isothiocyanate-conjugated IgG (Chemicon;
1:100) were used. Nuclei were counterstained with 4,6-
diamidino-2-phenylindole (DAPI) (Vectashield mount-
ing medium with DAPI; Vector Laboratories). Analysis
of CD133 was performed by flow-cytometry using an
anti-CD133 phycoerythrine conjugated antibody (clone
AC133-PE, mouse IgG1, Miltenyi Biotec). All the GSC
lines tested in this study were positive for SOX2,
Musashi-1 and nestin, whereas they expressed different
levels of CD133 (data not shown).
The human GBM cell lines U87 and SJGBM-2 were cul-
tured in DMEM supplemented with 10% fetal calf serum,
2 mM L-glutamine, 100 units/ml penicillin and 100 μg/ml
streptomycin (Sigma-Aldrich) at 37°C in a 5% CO2 humidi-
fied atmosphere. U87 was purchased from ATCC-LGC and
SJGBM-2 cell line was a gift from Dr. Peter J. Houghton
(St. Jude Children’s Research Hospital, Memphis, TN).
Drugs
The stock solution of TMZ (100 mM, Sigma-Aldrich) was
prepared by dissolving the drug in dimethyl sulfoxide
(DMSO). The final concentration of DMSO was always less
than 0.5% (v/v) and did not contribute to toxicity. The
PARPi GPI 15427 [10-(4-methyl-piperazin-1-ylmethyl)-2H-
7-oxa-1,2-diaza-benzo[de]anthracen-3-one, Eisai] stock so-
lution (1 mM) was prepared by dissolving GPI 15427 in
70 mM PBS without potassium [10].
Drug treatment and analysis of cell growth
Cytotoxicity assays were performed in 96-well plates.
GSCs were mechanically dissociated and plated at a
density of 2.4×104/ml, in triplicate for each treatment.
Compounds were added 3 hours after seeding. Cell via-
bility was estimated after 7 days by the chemilumines-
cence assay CellTiter-Glo™ (Promega Inc.) following
manufacturer’s instructions. Vehicle control (DMSO)
luminescence values were averaged and arbitrarily set to
100%. The absolute values of luminescence for each
treatment were then normalized with respect to vehicle
control and expressed as a percentage.To evaluate doubling times, mechanically dissociated
GSCs were plated in 96-well plates in triplicate and then
incubated at 37°C in a 5% CO2 incubator. Cell prolifera-
tion was monitored by counting cell number at different
time points and confirmed by using the CellTiter-Blue
Viability Assay (Promega Inc.).
Western blot analysis
For immunoblot analysis the following primary antibodies
were used: monoclonal anti-human MLH1 (clone G168-15,
BD Biosciences; 1:500); monoclonal anti-human MSH2
(clone GB12, Calbiochem; 1:1000); monoclonal anti-human
MSH6 (clone 44/MSH6, BD Biosciences; 1:500); mono-
clonal anti-calf PARP-1 (clone C2-10; Trevigen; 1:2000
dilution); monoclonal anti-human PTEN (clone 6H2.1;
Cascade Bioscience; 1:1000); goat polyclonal anti-human
MGMT (C20; Santa Cruz Biotechnology Inc; 1:1000);
rabbit polyclonal anti-human β-tubulin (H-235; Santa
Cruz Biotechnology; 1:400). Goat anti-rabbit (Biorad) and
goat anti-mouse IgG (Biorad) horseradish peroxidase
(HRP)-conjugated secondary antibodies were used at the
appropriate dilutions. Immunoreactive bands were de-
tected by enhanced chemoluminescence (ECL) technique
using the ECL Plus Western Blotting Substrate (Pierce).
Signals were quantified using a Kodak densitometer.
PARP activity assay
Cells (5×106) were lysed in 0.5 ml of a buffer containing
0.1% Triton X-100, 50 mM Tris–HCl pH 8, 0.6 mM EDTA,
14 mM β-mercaptoethanol, 10 mMMgCl2 and protease in-
hibitors. Proteins (25 μg) were incubated with 2 μCi 32P-
NAD+ (PerkinElmer), 100 μM NAD+, 50 mM Tris–HCl,
10 mM MgCl2, 14 mM β-mercaptoethanol, in the presence
of 10 μg nuclease-treated salmon testes DNA (maximally
stimulated activity). After 15 minutes at 30°C the reaction
was stopped adding ice-cold trichloroacetic acid 20% (v/v).
The radioactivity associated with the acid-insoluble mater-
ial, corresponding to poly(ADP-ribosyl)ated proteins, was
counted on a liquid scintillation counter. PARP activity was
evaluated as fmol of 32P-NAD+/μg of protein.
MGMT activity assay and bisulfite sequencing analysis of
MGMT promoter methylation
Cells (1×106) were lysed in 0.5 ml of a buffer containing
0.5% 3-[(3-cholamidopropyl) dimethylammonio]propane-
sulfonate, 50 mM Tris–HCl pH 8, 1 mM EDTA, 3 mM
dithiothreitol, 100 mM NaCl, 10% glycerol, protease inhib-
itors and incubated at 4°C for 30 minutes. Various
amounts of cell extracts were incubated with 10 μg of calf
thymus DNA previously labeled with N-[3H]-methyl-N-
nitrosourea (18 Ci/mmol; GE Healthcare). MGMT activity
was determined by measuring the transfer of [3H]-methyl
groups from methylated DNA to MGMTand expressed as
fmol of methyl groups per mg of proteins in cell extract.
Table 1 Characteristics of the original GBMs from which
GSCs were derived
GCS line WHO
classification
Tumor
location
Primary (P)
recurrent (R)
Overall survival
(months)
#144 Grade IV Temporal R 19
#62 Grade IV Frontal R 14
#1 Grade IV Temporal P 12
#28 Grade IV Frontal P 11
#74 Grade IV Frontal P 8
#83 Grade IV Temporal P 8
#30 Grade IV Frontal P 7
#61 Grade IV Occipital P 6
#23 Grade IV Parietal P 3
#148 Grade IV Parietal R 1
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(Qiagen) and converted for bisulfite sequencing analysis
using EZ DNA Methylation Kit (Zymo Research) fol-
lowing manufacturer instructions. Bisulfite modified
DNA was amplified using the following primer pair:
MGMT-C-Bis forward, 5′-GGATATGTTGGGATAG
TT-3′; and MGMT-C-Bis reverse, 5′-AAACTAAACAA
CACCTAAA-3′. Amplification reaction was performed
using 5 PRIME HotMasterMix with the following condi-
tions: 95°C for 4 minutes, followed by 42 cycles of 95°C
for 30 seconds, 47°C for 30 seconds and 65°C for 30 sec-
onds, with a final extension of 65°C for 5 minutes. Ampli-
fied fragments were cloned into the TOPO TA-cloning
vector (Invitrogen) and fifteen clones for each GSC line
were sequenced by Eurofins MWG Operon service.
Statistical analysis
The statistical analysis of the differences in drug sensi-
tivity among the cell lines was performed using ANOVA
followed by Bonferroni’s post-test and the non-
parametric Kruskal-Wallis analysis followed by Dunn’s
post-test for multiple comparisons; a P value of less
than 0.05 was considered significant. To evaluate
whether the combination TMZ + PARPi was synergic,
cells were exposed to TMZ alone or in combination
with a fixed concentration of GPI 15427. The experi-
ments were performed in quadruplicates and repeated
three times. The dose-effect curves were analyzed by
the median-effect method of Chou and Talalay using
the Calcusyn Software as a non-constant ratio combin-
ation (Biosoft). The combination index (CI) indicates a
quantitative measure of the degree of drug interaction
in terms of synergistic (CI < 1), additive (CI = 1) or an-
tagonistic effect (CI > 1) [22]. Correlation analyses
were performed using the Spearman’s rank test and
significance was determined according to P values
(SSPS software).
Results
Analysis of determinants of resistance to TMZ in GSCs
Ten patient-derived GSC lines (Table 1) and two GBM
cell lines (U87 and SJGBM-2) were characterized for the
expression of the MMR components MLH1, MSH2 and
MSH6, involved in the processing and toxicity of O6-
methylguanine, and of MGMT, responsible for the
removal of the O6-methyl adduct. In fact, the lack of ex-
pression of one of MMR components and/or the presence
of high MGMT levels are associated with resistance to
TMZ. The results of Western blot analysis indicated that
only the SJGBM-2 cell line was MMR-deficient, lacking
MSH2 and MLH1 expression (Figure 1A). Concerning
MGMT, the #61, #83, #148 and #30 GSC lines showed the
highest expression, whereas #74, #62, #144, #23, U87 and
SJGBM-2 lines showed low or barely detectable MGMTprotein. The #28 and #1 GSC lines, instead, were character-
ized by intermediate levels of the repair enzyme (Figure 1B).
Analysis of MGMT activity by measuring the ability of cel-
lular extracts to remove methyl adducts from the O6 pos-
ition of guanine in a methylated DNA substrate (Figure 1C)
revealed a direct correlation between MGMT activity and
protein expression in GCS and GBM cell lines (Spearman’s
correlation = 0.87, P < 0.0001, n = 12). In addition, DNA
methylation analysis of MGMT CpG island was performed
focusing on the region downstream of the transcription
start site, which is most commonly investigated by the
methylation-specific PCR assay [7,23]. The bisulfite sequen-
cing method was chosen to obtain an unambiguous single-
base resolution of DNA methylation status. Notably,
MGMT promoter methylation inversely correlated with
MGMT activity and expression in GSC lines (Spearman’s
correlation = −0.82, P = 0.004 and −0.76, P = 0.01, respect-
ively, n = 10). In particular, the GSC lines with ≥200 fmol/
mg MGMT activity were characterized by an unmethy-
lated MGMT promoter (Figure 1D and Table 2). The #74
GSC line showed a modest level of promoter methylation
that did not match with the low MGMT expression/activ-
ity (Table 2). Considering that the methylation status of re-
gions upstream of the transcription start site may also
influence MGMT expression [24,25], DNA methylation
analysis of the #74 GSC line was extended to the entire
CpG island. However, also upstream regions showed very
low levels of DNA methylation (data not shown). The
MGMT promoter of U87 GBM cell line was heavily meth-
ylated [26].
Chemosensitivity to TMZ was evaluated by measuring
ATP production, as a marker of metabolically active cells.
Results indicated that most GSC lines with high MGMT
activity (≥200 fmol/mg) showed low sensitivity to TMZ,
with IC50s >300 μM, a value which is well above the peak
plasma concentration reached in cancer patients (20–
96 μM at a TMZ dose of 200 mg/m2) [28]. The #74, #28
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Figure 1 Analysis of MMR components and MGMT in GSC and GBM cell lines. Immunoblot analysis of MLH1 (black column), MSH2 (grey
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D.) of the protein of interest and those of tubulin. The results are representative of one out of two experiments with similar results. SJ: SJGBM-2.
Panel C. Analysis of MGMT activity. MGMT activity is expressed as fmol of methyl groups per mg of total protein and data are the mean (± SD) of
three independent experiments. Panel D. Analysis of MGMT promoter methylation. Summary of bisulfite sequencing in 10 GSC lines. A total of 27
CpG dinucleotides (CpGs) within the promoter region of MGMT were analyzed and are represented as circles. Each row refers to one individual
cell line and circle color indicates the percentage of methylation of each CpG calculated on 15 clones analyzed for each cell line. Closed circles
represent fully methylated cytosines, open circles represent fully unmethylated cytosines and grey scale circles represent the indicated
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TMZ with IC50s comprised between 3 and 90 μM,
whereas the #62 and #148 GSC lines possessed inter-
mediate sensitivity (200–300 μM) to the methylating agent
(Figure 2A). Finally, the GBM U87 cell line, which is MMR-
proficient and MGMT-deficient, showed higher sensitivity
in comparison with the MMR-deficient SJGBM-2 cell line
(Figure 2A). Since actively proliferating cells are more sus-
ceptible to TMZ [5,29], the doubling times of the different
GSC and GBM lines were measured (Figure 2B) and the re-
sults indicated that they ranged from 20 to 108 hours, being
#23 the GSC line with the lowest proliferation rate. Inte-
restingly, when GSC lines with similar MGMT activity
(<150 fmol/mg) were compared, the cell line with lowerproliferative potential resulted more resistant to TMZ (e.g.,
#23 versus #144; #1 versus #28; #62 versus #74) (Figure 2).
Overall, the response of GSC and GBM cell line to TMZ
did not significantly correlate with MGMT activity. How-
ever, excluding from the analysis the GSC and GBM cell
lines resistant to TMZ for mechanisms unrelated to
MGMTstatus, such as the extremely low proliferation rate
(i.e., #23 GSC) or MMR deficiency (i.e., SJGBM-2), sensi-
tivity to TMZ inversely correlated with MGMT activity
levels (Spearman’s correlation = 0.79, P = 0.006; n = 10).
Excluding from the analysis the slow proliferating #23
GSC line, which is resistant to TMZ even though it lacks
MGMT activity, MGMT activity/expression by GSCs in-
versely correlated with the overall survival of patients from
Table 2 Relationship between MGMT expression/activity and MGMT promoter methylation in GSC lines
GSC MGMT/Tubulin MGMT activity (fmol/mg) CpG 73 CpG 75 CpG 79 CpG 80 CpG 83 CpG 86 CpG 87 CpG 89 CpG mediana
#62 0.1 40 83.3 83.3 100 100 100 100 100 100 100
#144 0.01 1 50 100 100 100 100 100 83.3 83.3 83.3
#28 0.69 152 70 70 70 60 70 50 80 60 60
#23 0.01 1 0 100 16.7 100 66.7 100 100 50 33.3
#1 0.45 139 70 70 50 60 40 30 60 50 30
#74 0.04 81 12.5 25 0 25 0 12.5 62.5 37.5 12.5
#83 1.38 247 0 0 0 0 0 0 0 0 0
#30 1.67 200 0 0 0 0 0 0 0 0 0
#148 1.72 210 0 0 0 0 0 0 14.3 0 0
#61 1.43 240 0 0 0 0 0 0 0 0 0
aMedian value of DNA methylation of all 27 CpGs analyzed by bisulfite sequencing.
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Spearman’s correlation = −0.79, P = 0.01; for MGMT pro-
tein expression, Spearman’s correlation = −0.85, P = 0.003;
n = 9). Noteworthy, promoter methylation status of all the
GSC lines directly correlated with patients’ overall survival
(Spearman’s correlation = 0.71, P = 0.02, n = 10) (Figure 3).Figure 2 Sensitivity of GSC lines to TMZ as single agent. Panel A. Chem
7 days after drug exposure. Data were plotted in 4 different graphs which
TMZ IC50s comprised between 200 and 300 μM (#148, #62), with TMZ IC50
The results are expressed as survival fraction and are the mean (± SD) of th
GBM cell lines. Data are the mean (±SD) of three independent determinatioAnalysis of PTEN and PARP-1 activity/expression and
sensitivity to PARPi monotherapy in GSCs
Cell lines were analyzed for PARP-1 and PTEN expression
by Western blotting and for sensitivity to PARPi mono-
therapy. In regard to PARP-1, the #148, #23 and #144
GSC lines showed the highest, whereas #61, #62 and 30#osensitivity of GSC and GBM cell lines. Tumor growth was evaluated
gather GSC lines with TMZ IC50s >300 μM (#23, #83, #1, #61, #30), with
< 100 μM (#74, #28, #144) and the two GBM cell lines (SJGBM-2, U87).
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(Figure 4B) in GSC and GBM lines significantly correlated
with the expression of PARP-1 protein (Spearman’s correl-
ation = 0.72, P = 0.008, n = 12) that accounts for more
than 90% of total cellular poly(ADP-ribosyl)ating activ-
ity [12]. On the other hand, PTEN was expressed
in #83, #23 and #28 GSC lines, only (Figure 4A); this
finding is consistent with the high frequency of PTEN
mutations or loss at 10q23 locus reported for GBM
[16]. The #83 and #61 GSC were the most resistant
ones, whereas #30 and #62 GSC were the most sensi-
tive to the PARPi [P < 0.01, according to ANOVA (α =
0.05) followed by Bonferroni’s post-test and to the
non-parametric Kruskal-Wallis analysis followed by
Dunn’s post-test] (Figure 4C). Sensitivity of GSC to
PARPi did not correlate either with PARP-1 or PTEN
expression. The U87 and SJGBM-2 cell lines were
characterized by low PARP-1 levels, but they differed
in PTEN expression and PARPi sensitivity. In fact,
SJGBM-2 cells were PTEN-proficient and more resist-
ant to PARPi than U87 cells (Figure 4).
PARPi potentiates GSC sensitivity to TMZ
With the aim of investigating whether the interruption of
N-methylpurine repair by PARPi might revert GSCresistance to TMZ, GSC lines were treated with graded
concentrations of TMZ in combination with a fixed dose
of the PARPi GPI 15427 that inhibits in living cells more
than 80% of PARP activity (5 μM in the case of the #83
and #61 GSC lines, which are the most resistant to PARPi,
and 2.5 μM for all the other cell lines) [30]. The drug com-
bination resulted in synergistic effects in 8 out of 10 GSC
lines with CI comprised between 0.27 and 0.76 (Figure 5A).
Analysis of the dose reduction index (DRI) indicated that
addition of PARPi to the methylating agent in GSC lines
allowed up to 3.3-fold reduction of TMZ IC50. The PARPi
increased TMZ efficacy also in both GBM U87 and
SJGBM-2 cell lines; the potentiating effect was more pro-
nounced in the latter cells which were more resistant to
TMZ as compared to U87 cells because of MMR defi-
ciency (Figure 1A). Interestingly, the DRI of TMZ sig-
nificantly correlated with the sensitivity of each cell line
to the treatment with PARPi as single agent (Figure 5B).
In GSCs with the lowest response to PARPi monother-
apy, i.e., #83 and #61, PARPi did not enhance the antitu-
mor activity of TMZ.
Discussion
Although PARPi have been shown to increase the antitu-
mor efficacy of TMZ against a variety of tumor types, the
A
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Figure 4 PARP-1 and PTEN expression in GSC lines and sensitivity to PARPi monotherapy. Panel A. Immunoblot analysis of PARP-1 and
PTEN proteins. Bars represent the mean ratios between the O.D. of PARP-1 and those of tubulin. The results are representative of one out of two
experiments with similar results. Panel B. Analysis of total cellular PARP activity. Maximally stimulated PARP activity was measured in cell extracts
obtained from GSC and GBM cell lines in the presence of nuclease-treated salmon testes DNA and 32P-NAD+ as described in Methods. PARP
activity was expressed as fmol 32P-NAD+/μg of protein and the results are the mean (± SD) of triplicate determinations. Panel C. Sensitivity to
PARPi. Tumor cells were treated with graded concentrations of GPI 15427 (0.5-50 μM) as single agent and analyzed 7 days after drug exposure.
Bars represent the PARPi IC50 values and are the mean (± SD) from three independent experiments.
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been investigated. In the present study, we demonstrate for
the first time that PARP-1 can be efficiently targeted in hu-
man GSCs in order to increase the sensitivity of these cells
to TMZ. More specifically, in eight out of ten GSC lines
PARPi allowed up to a 3-fold reduction of TMZ IC50s.
We found that all GSCs are MMR-proficient and the re-
sistance to TMZ is mainly caused by an efficient repair of
methyl adducts from O6-guanine. Seven GSC lines showed
TMZ IC50s between 200 and 600 μM that are markedly
above the peak plasma concentration reached in cancer pa-
tients. Only one GSC line (i.e., #23) was resistant to the
methylating agent despite MMR-proficiency and lack of
MGMT activity/expression. This might be attributed to the
extremely low proliferation rate of the #23 line. Cell lines
with comparable medium/low MGMTactivity but different
proliferation rate showed dissimilar TMZ susceptibility. In
fact, cytotoxicity related to the processing of O6-methylgua-
nine takes place only during the second cycle of DNA repli-
cation that follows adduct generation. The presence of a
non-proliferating compartment in the tumor mass may
limit the efficacy of TMZ as monotherapy even in the caseof malignancies with functional MMR and low MGMT
activity. On the other hand the killing effect, deriving
from interruption of BER-mediated repair process of N-
methylpurines by PARPi, may occur even during the first
round of cell division and in the absence of DNA synthesis
[29]. Indeed, PARPi potentiated the sensitivity to TMZ also
in slow proliferating GSCs. Excluding the slow proliferating
#23 GSC line, the anti-tumor effects of TMZ in MMR-
proficient cell lines inversely correlated with MGMT activ-
ity/expression at a statistically significant level.
Epigenetic silencing of MGMT expression is regarded as
a prognostic factor and valuable predictive marker of TMZ
efficacy in GBM [7,31]. CpG methylation in the MGMT
promoter of the GSC lines ranged from 0% to 100% and all
GSC lines with a MGMT promoter containing 0%
methylated CpGs showed very high enzymatic activity
(≥200 fmol/mg) and resistance to TMZ. Interestingly,
the percentages of CpG methylation in the promoter of
GSCs significantly correlated with patients’ overall sur-
vival. Although statistical analysis indicated an inverse
correlation between MGMT promoter methylation
and MGMT activity, in #74 GSC the entire CpG island
Cell line
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CI (62.5 – 250 
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U87 0.57-0.76 2.59
SJGBM-2 0.34-0.63 5.57
#144 0.47-0.61* 2.7
#28 0.53-0.76 1.98
#74 0.67-0.74 1.71
#62 0.69-0.76 3.35
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Figure 5 Modulation of GSC sensitivity to TMZ by PARPi. Panel A. GCS and GBM cell lines were exposed to graded concentration of TMZ as
single agent or in combination with a fixed dose of PARPi GPI 15427. Bars represent the TMZ IC50 values as single agent (black column) or in
combination with PARPi (grey column) and are the mean (± SD) from three independent experiments. The table indicates the values of
combination index (CI) for a TMZ concentration range of 62.5-250 (*1.9-7.8 μM in the case of #144 GSC line), evaluated according to the
Chou-Talalay method to determine synergy. The DRI values refer to the fold decrease of TMZ IC50 obtainable when the methylating agent was
combined with the PARPi. Panel B. Relationship between PARPi IC50 in GSC lines and the DRI (TMZ) in combination with a fixed dose of PARPi.
The Spearman’s correlation coefficients and their significance levels are indicated.
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http://www.biomedcentral.com/1471-2407/14/151was mainly demethylated despite low MGMT activity
(<100 fmol/mg)/protein expression and high TMZ sensi-
tivity (IC50 < 100 μM). This evidence may depend on a
DNA methylation-independent mechanism based on al-
tered chromatin configuration and gene silencing de-
scribed for MGMT [32]. In this case the sole analysis of
MGMT promoter methylation status would have led to
underestimation of tumor chemosensitivity. Our findings
are in agreement with a recent report indicating that de-
termination of both promoter methylation and protein ex-
pression is required for an optimal assessment of MGMT
status [33]. Nevertheless, the short overall survival of thepatient, from whom #74 GSC derives, appears to match
with the promoter demethylated pattern, thus confirming
the importance of the MGMT promoter methylation as
prognostic factor [34]. Interestingly, excluding the GSC
line resistant to TMZ as a consequence of the extremely
low proliferation rate (i.e., #23), also MGMT activity/ex-
pression was inversely related with patients’ overall sur-
vival at a statistically significant level.
Sensitivity of tumors to PARPi monotherapy has been
recently linked to PARP-1 expression, suggesting that
for a NAD+ competitor to be functional, enough PARP-
1 target must be available to bind DNA strand breaks
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http://www.biomedcentral.com/1471-2407/14/151and synthesize poly(ADP-ribose) [35]. The susceptibility
of GSC lines to PARPi did not correlate with PARP-1 pro-
tein levels or with total cellular PARP activity. Actually,
the most resistant lines (i.e. #83 and #61) were character-
ized by PARP activity comparable to that of the most sen-
sitive GSC lines (i.e. #30 and #62). These data suggest that
PARP-1 expression itself is not a limiting factor for PARPi
efficacy in GSC lines.
Alterations in PTEN gene on 10q23 at the level of loss
of heterozygosity, mutation and methylation have been
identified in at least 60% of GBMs [16]. In agreement with
these findings, PTEN was not expressed in the majority (7
out of 10) of the GSC lines tested. Lack of PTEN expres-
sion has been recently associated with increased sensitivity
to PARPi monotherapy according to a synthetic lethality
model [36]. Even though the highly sensitive #30 and #62
GSC lines did not express PTEN, no statistically signifi-
cant correlation was found between PARPi IC50 of all the
GSC lines and PTEN protein expression. These results are
consistent with data reported for prostate cancer in which
PTEN status did not behave as a biomarker for HR func-
tion and response to PARPi [37]. Since the lack of PTEN
protein expression in GSC or GBM cells may derive from
PTEN gene mutations or from deletion of chromosome
band 10q23 involving other genes, we cannot exclude that
the mutation status and copy number changes might have
different roles in the sensitivity to PARPi.
Treatment with the PARPi enhanced TMZ efficacy in
all but two GSC lines and the potentiating effect directly
correlated with sensitivity of each cell line to the PARPi
used as single agent. In fact, the #30 and #62 GSC lines,
which were sensitive to GPI 15427, became highly vul-
nerable to the combination of TMZ and PARPi. The two
GSC lines (#83 and #61) in which TMZ and PARPi asso-
ciation did not result in synergistic effects were the most
resistant to PARPi monotherapy and were poorly re-
sponsive to TMZ as well. The PARPi used in our study
GPI 15427 and its analogue E7016 have shown ability to
cross the blood–brain barrier and chemo-radiosensitizing
activity in preclinical models of glioblastoma [10,11].
E7016 is currently under clinical investigation in association
with TMZ for solid tumors comprising gliomas (phase I,
NCT01127178) and metastatic melanoma including cere-
bral metastases (phase II, NCT01605162) (www.clinical-
trials.gov). The PARPi provoked a remarkable dose
reduction of TMZ in the MMR-deficient SJGBM-2 cells,
and such reduction was higher than that obtained in the
MMR-proficient U87 GBM cells. This finding suggested
that the chemosensitizing effect is maximal in tumor cells
tolerant to O6-methylguanine, which is regarded as the
main cytotoxic adduct generated by TMZ. In MMR-
deficient GBM cells inhibition of PARP catalytic activity
converts N-methylpurines in cytotoxic lesions since they
are no longer repaired by BER [38].It was previously demonstrated that tumor clones se-
lected for resistance to PARPi plus TMZ expressed lower
levels of PARP-1 as compared to parental sensitive cells
[39]. In our GSC model PARP-1 expression/activity did
not appear to influence chemosensitization mediated by
the PARPi. Indeed, we have recently found that inhibition
of PARP-1 function increased the antitumor activity of
platinum compounds or topoisomerase I poisons even in
the presence of low PARP-1 expression [40,41].
Conclusions
In conclusion, the combination of TMZ with PARPi is a
valuable strategy to counteract chemoresistance of GSCs
which contributes to treatment failure and tumor recur-
rence in GBM patients.
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